The sequencing of protein-coding exons, e.g., KRAS, BRAF and PIK3CA, in circulating tumor DNA (ctDNA) samples from MM patients revealed that it predicted 96% of mutations detected in matched BM-derived tumor DNA samples with >98% specificity [113]. Here, KRAS is linked to neoplasm.